Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,247.00 -30.51 (-0.58%) Dow
38,298.24 -388.08 (-1.00%) Nasdaq
16,692.10 -42.92 (-0.26%) Bitcoin USD
69,049.38 +1,004.80 (+1.48%) CMC Crypto 200
1,485.35 +17.42 (+1.19%)
LLY Jan 2025 710.000 put
| Previous close | 27.82 |
| Open | 27.82 |
| Bid | 23.85 |
| Ask | 25.25 |
| Strike | 710.00 |
| Expiry date | 2025-01-17 |
| Day's range | 27.82 - 27.82 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
Eli Lilly, T-Mobile US, BHP, American International and Exelon are part of the Zacks Analyst Blog.
PR NewswireUpdated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
ZacksTop Research Reports for Eli Lilly, T-Mobile & BHP
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
